<code id='30C4C543EF'></code><style id='30C4C543EF'></style>
    • <acronym id='30C4C543EF'></acronym>
      <center id='30C4C543EF'><center id='30C4C543EF'><tfoot id='30C4C543EF'></tfoot></center><abbr id='30C4C543EF'><dir id='30C4C543EF'><tfoot id='30C4C543EF'></tfoot><noframes id='30C4C543EF'>

    • <optgroup id='30C4C543EF'><strike id='30C4C543EF'><sup id='30C4C543EF'></sup></strike><code id='30C4C543EF'></code></optgroup>
        1. <b id='30C4C543EF'><label id='30C4C543EF'><select id='30C4C543EF'><dt id='30C4C543EF'><span id='30C4C543EF'></span></dt></select></label></b><u id='30C4C543EF'></u>
          <i id='30C4C543EF'><strike id='30C4C543EF'><tt id='30C4C543EF'><pre id='30C4C543EF'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:8

          Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally back?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we delve into the fallout over the FTC’s move to block what looked like a humdrum biotech deal between Sanofi and Maze Therapeutics, a surprising twist that leaves an unanswered question. We also discuss the latest news in the life sciences, including Pfizer’s downbeat future, Vertex Pharmaceuticals’ next big thing, and a newly minted biotech VC with a very famous name.

          advertisement

          For more on what we cover, here’s the FTC news; here’s more from Maze Therapeutics; here’s the Pfizer news; here’s the latest on Vertex; here’s the story behind its pain drug; here’s the Reed Jobs profile; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          comprehensive

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          Decentralized clinical trials need collaboration to achieve wider use
          Decentralized clinical trials need collaboration to achieve wider use

          AdobeDespitegroundbreakingadvancesinbasicandclinicalscienceandtechnology,clinicaltrialmethodshavenot

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          FDA warns J&J's Abiomed: We will regulate your software

          Abiomed,whichwasboughtbyJohnson&Johnsonlatelastyearfor$16.6billion,sellsdevicesforheartfailurepa